Arcus Biosciences (NYSE:RCUS) Research Coverage Started at SunTrust Banks
SunTrust Banks started coverage on shares of Arcus Biosciences (NYSE:RCUS) in a research report released on Tuesday, Briefing.com Automated Import reports. The brokerage issued a buy rating and a $20.00 price objective on the stock.
Other research analysts have also issued research reports about the stock. Mizuho reaffirmed a buy rating and set a $22.00 price objective on shares of Arcus Biosciences in a research report on Monday, November 11th. ValuEngine raised shares of Arcus Biosciences from a hold rating to a buy rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research lowered shares of Arcus Biosciences from a buy rating to a hold rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Arcus Biosciences presently has an average rating of Buy and an average price target of $17.35.
Shares of RCUS traded down $0.32 during trading hours on Tuesday, reaching $7.65. 72,356 shares of the company traded hands, compared to its average volume of 248,848. The stock’s fifty day moving average is $8.29 and its 200 day moving average is $8.45. The stock has a market cap of $366.41 million, a P/E ratio of -5.35 and a beta of 0.99. Arcus Biosciences has a 1-year low of $6.30 and a 1-year high of $13.77.
Large investors have recently bought and sold shares of the stock. GSA Capital Partners LLP increased its holdings in shares of Arcus Biosciences by 17.3% during the second quarter. GSA Capital Partners LLP now owns 16,243 shares of the company’s stock worth $129,000 after buying an additional 2,392 shares in the last quarter. Aperio Group LLC acquired a new stake in shares of Arcus Biosciences during the second quarter worth approximately $32,000. Meeder Asset Management Inc. increased its holdings in shares of Arcus Biosciences by 672.9% during the third quarter. Meeder Asset Management Inc. now owns 4,939 shares of the company’s stock worth $46,000 after buying an additional 4,300 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Arcus Biosciences by 10.5% during the third quarter. Rhumbline Advisers now owns 48,859 shares of the company’s stock worth $445,000 after buying an additional 4,660 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Arcus Biosciences by 32.9% during the third quarter. Russell Investments Group Ltd. now owns 21,315 shares of the company’s stock worth $195,000 after buying an additional 5,278 shares in the last quarter. 46.83% of the stock is owned by hedge funds and other institutional investors.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Featured Story: Trading based on a resistance level
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.